Who is sponsoring NCT01275287?

NCT01275287 is sponsored by University of North Carolina, Chapel Hill.

What condition does NCT01275287 study?

NCT01275287 studies Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.

What drugs are being tested in NCT01275287?

Interventions: Standard of care treatment, eculizumab.

What is the status of NCT01275287?

NCT01275287 is currently WITHDRAWN.

Last reviewed 2017-02-17 · How we verify

Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis

NCT01275287 Phase 2 WITHDRAWN

The purpose of this research study is to see if Eculizumab (Soliris®) can safely be used in addition to conventional therapy in patients with active ANCA (Antineutrophil Cytoplasmic Autoantibodies ) vasculitis and lead to a more rapid decrease in disease activity. ANCA vasculitis is an inflammation of the small vessels whereby ANCA antibodies inappropriately activate one's own white blood cells (neutrophils) and cause damage to the small blood vessels.

Details

Lead sponsor	University of North Carolina, Chapel Hill
Phase	Phase 2
Status	WITHDRAWN
Start date	2011-05
Completion	2012-12

Conditions

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Interventions

Standard of care treatment
eculizumab

Primary outcomes

Birmingham Vasculitis Activity Score (BVAS) — 12 weeks
Change in disease activity as measured by BVAS at 12 weeks.

Countries

United States